Gujarat Themis Biosyn Limited reported a net profit of ₹4,668.15 lakh for the financial year ended March 31, 2026, compared to ₹4,877.17 lakh in the previous year. Total income for the year rose to ₹16,825.09 lakh from ₹15,323.23 lakh in FY25. The Board of Directors, meeting on May 25, 2026, approved the audited financial results and recommended a final dividend of Re. 0.67 per equity share for the fiscal year.

Financial Performance

For the quarter ended March 31, 2026, the company recorded a net profit of ₹1,089.12 lakh. Income from operations for the quarter stood at ₹4,423.30 lakh, while total income was ₹4,515.41 lakh. For the full year, income from operations increased to ₹16,582.28 lakh from ₹15,079.99 lakh in the previous year.

Dividend Recommendation

The Board has recommended a final dividend of Re. 0.67 per equity share, representing 67% of the face value of Re. 1 each. The total dividend payout aggregates to ₹7,30,06,728 and is subject to the approval of shareholders at the ensuing Annual General Meeting.

Corporate Developments

The Board approved the appointment of M/s. Raja Dutta & Co., Cost Accountants, as the Cost Auditor for the financial year 2026-27. Additionally, the board approved a proposal for a preferential issue of equity shares to Non-Promoters. A Preferential Issue Committee has been constituted to finalize the terms and conditions of the proposed issue, subject to necessary regulatory and shareholder approvals.

Gujarat Themis Biosyn Limited reported its financial results for the quarter and fiscal year ended March 31, 2026. The company concluded the fiscal year with robust volume growth and operational efficiencies, leading to margin expansion. For Q4 FY26, revenue from operations increased 17.22% year-on-year to Rs 44.23 crore. EBITDA for the quarter rose 20.71% to Rs 19.36 crore, with an EBITDA margin of 43.79%. Profit After Tax (PAT) stood at Rs 10.89 crore, and the EPS for the quarter was Rs 1.00.

Quarterly Financial Highlights

The following table summarizes the company's key financial metrics for Q4 FY26 compared to Q4 FY25:

Annual Performance

For the full year FY26, the company reported revenue from operations of Rs 165.82 crore, a growth of 9.96% compared to the previous year. EBITDA for the year was Rs 75.53 crore, while PAT stood at Rs 46.68 crore. The annual EPS was recorded at Rs 4.28. The management attributed the performance to optimized production, higher sales volumes, and cost rationalizations which offset rising manpower costs.

Strategic Expansion Initiatives

The company is pursuing significant inorganic expansion to complement its organic growth. It has signed an asset purchase agreement to acquire a portfolio of 13 brands from Sanofi, France, for approximately EUR 158 million. This asset-light acquisition is expected to be EPS accretive and provide immediate access to regulated markets across 55+ countries. Additionally, the company has signed a share purchase agreement to acquire 100% of MicroBiopharm Japan Co., Ltd. for JPY 21.5 billion (approximately INR 1,300 crores). This transaction, expected to close in Q2 FY2027, will enhance its CDMO capabilities and biotechnology know-how.

Capex and Future Outlook

The company continues to invest in capacity expansion and sustainability. Its R&D and API units are operational, and a new fermentation block development is complete. R&D spend for FY26 was approximately 9% of the topline. Furthermore, the company is establishing a hybrid wind-solar power plant in Gujarat with a capacity of ~18 MW for captive consumption, aimed at reducing power costs and carbon footprint.